OBJECTIVE: To examine whether decreased serum levels of adiponectin are an independent risk factor for the progression to type 2 diabetes in a Japanese population. RESEARCH DESIGN AND METHODS: The serum levels of adiponectin and tumor necrosis factor-alpha (TNF-alpha) at baseline (from 1995 to 1997) were evaluated in 1,792 individuals (1,023 women and 769 men, aged 58.5 +/- 12.5 years) from a cohort population (n = 3,706) of the Funagata study. Glucose tolerance was evaluated at baseline and also at 5-year follow-up examinations (n = 978, follow-up rate, 54.6%) according to the 1985 World Health Organization criteria. The correlation of clinical traits with serum levels of adiponectin was examined. The association of the traits with the progression to type 2 diabetes at the 5-year follow-up was also examined. RESULTS: Among the traits examined, the correlation with aging was highest (r = 0.312, P < 0.001). Eighteen subjects with normal glucose tolerance (NGT) developed diabetes, and 709 remained NGT at the 5-year follow-up examinations. The subjects who became diabetic had decreased serum levels of adiponectin (7.29 +/- 2.35 vs. 9.13 +/- 2.35 10 x log microg/ml, P = 0.009). Multiple logistic regression analysis with age, sex, waist-to-hip ratio, and 2-h plasma glucose as the variables revealed that serum adiponectin level (odds ratio [per 0.1 log microg/ml] 0.766, P = 0.029) was an independent risk factor for the progression to type 2 diabetes. The subjects whose serum levels of adiponectin were in the lowest tertile were 9.320 times (95% CI 1.046-83.1) more likely to develop diabetes than those in the highest tertile (P = 0.046). CONCLUSIONS: Decreased serum adiponectin level is an independent risk factor for progression to type 2 diabetes.
OBJECTIVE: To examine whether decreased serum levels of adiponectin are an independent risk factor for the progression to type 2 diabetes in a Japanese population. RESEARCH DESIGN AND METHODS: The serum levels of adiponectin and tumor necrosis factor-alpha (TNF-alpha) at baseline (from 1995 to 1997) were evaluated in 1,792 individuals (1,023 women and 769 men, aged 58.5 +/- 12.5 years) from a cohort population (n = 3,706) of the Funagata study. Glucose tolerance was evaluated at baseline and also at 5-year follow-up examinations (n = 978, follow-up rate, 54.6%) according to the 1985 World Health Organization criteria. The correlation of clinical traits with serum levels of adiponectin was examined. The association of the traits with the progression to type 2 diabetes at the 5-year follow-up was also examined. RESULTS: Among the traits examined, the correlation with aging was highest (r = 0.312, P < 0.001). Eighteen subjects with normal glucose tolerance (NGT) developed diabetes, and 709 remained NGT at the 5-year follow-up examinations. The subjects who became diabetic had decreased serum levels of adiponectin (7.29 +/- 2.35 vs. 9.13 +/- 2.35 10 x log microg/ml, P = 0.009). Multiple logistic regression analysis with age, sex, waist-to-hip ratio, and 2-h plasma glucose as the variables revealed that serum adiponectin level (odds ratio [per 0.1 log microg/ml] 0.766, P = 0.029) was an independent risk factor for the progression to type 2 diabetes. The subjects whose serum levels of adiponectin were in the lowest tertile were 9.320 times (95% CI 1.046-83.1) more likely to develop diabetes than those in the highest tertile (P = 0.046). CONCLUSIONS: Decreased serum adiponectin level is an independent risk factor for progression to type 2 diabetes.
Authors: L Y Han; Q H Wu; M L Jiao; Y H Hao; L B Liang; L J Gao; D G Legge; H Quan; M M Zhao; N Ning; Z Kang; H Sun Journal: Diabetologia Date: 2011-06-03 Impact factor: 10.122
Authors: Birgit Klüppelholz; Barbara Thorand; Wolfgang Koenig; Tonia de Las Heras Gala; Christa Meisinger; Cornelia Huth; Guido Giani; Paul W Franks; Michael Roden; Wolfgang Rathmann; Annette Peters; Christian Herder Journal: Diabetologia Date: 2015-07-09 Impact factor: 10.122
Authors: Erica P Gunderson; Catherine Kim; Charles P Quesenberry; Santica Marcovina; David Walton; Robert A Azevedo; Gary Fox; Cathie Elmasian; Stephen Young; Nora Salvador; Michael Lum; Yvonne Crites; Joan C Lo; Xian Ning; Kathryn G Dewey Journal: Metabolism Date: 2014-04-13 Impact factor: 8.694
Authors: Anna V Goropashnaya; Johanna Herron; Mary Sexton; Peter J Havel; Kimber L Stanhope; Rosemarie Plaetke; Gerald V Mohatt; Bert B Boyer Journal: Metabolism Date: 2009-01 Impact factor: 8.694
Authors: Christin Heidemann; Qi Sun; Rob M van Dam; James B Meigs; Cuilin Zhang; Shelley S Tworoger; Christos S Mantzoros; Frank B Hu Journal: Ann Intern Med Date: 2008-09-02 Impact factor: 25.391